Département d'Oncologie Médicale, Université Paris Descartes, Hôpital Hôtel-Dieu, Paris, France.
Ann Oncol. 2011 Dec;22 Suppl 8:viii61-viii64. doi: 10.1093/annonc/mdr518.
In the absence of significant advance in first-line therapy until recently, the increased knowledge of how to manage relapse accounts for most of the advances observed in ovarian cancer during the last 10 years. In addition, a large number of new drugs, mostly in the category of 'targeted therapy', are currently being tested in the setting of recurrent ovarian and are expected to change the course of the disease in the near future. The acknowledgement of the platinum-free interval (PFI) as the major criterion predicting therapy success in ovarian cancer relapse has allowed the development of distinct therapeutic strategies according to the PFI length. This update will indicate the pivotal trials that have led to the largest steps in the management of recurrent ovarian cancer during the last 10 years. Future advances in ovarian cancer treatment need randomized phase II or phase III trials in the recurrent disease setting before being tested in first line. The main ongoing randomized trials in relapsed disease will be reviewed, focusing on phase II or phase III trials.
在最近之前，一线治疗方面没有重大进展，而对如何管理复发的认识的提高，是过去 10 年来卵巢癌领域取得进展的主要原因。此外，目前正在对复发性卵巢癌进行大量新的药物（主要是靶向治疗药物）的测试，预计这些药物将在不久的将来改变疾病的进程。将无铂间期（PFI）作为预测卵巢癌复发治疗成功的主要标准，使得根据 PFI 长度制定了不同的治疗策略。本更新将指出过去 10 年中在管理复发性卵巢癌方面取得最大进展的关键试验。在一线治疗中进行测试之前，卵巢癌治疗的未来进展需要在复发性疾病中进行随机 II 期或 III 期试验。将对正在进行的复发性疾病中的主要随机试验进行综述，重点是 II 期或 III 期试验。
